The Thetis Study: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Tradipitant on Nausea and Vomiting After GLP-1R Agonist Administration in Healthy Overweight or Obese Volunteers
Latest Information Update: 24 Apr 2026
At a glance
- Drugs Tradipitant (Primary)
- Indications Motion sickness; Nausea and vomiting
- Focus Registrational; Therapeutic Use
- Acronyms Thetis
- Sponsors Vanda Pharmaceuticals
Most Recent Events
- 08 Apr 2026 According to a Vanda Pharmaceuticals media release, topline results expected by Q4 2026. Following completion of the Thetis study, additional study data may be required prior to approval of a New Drug Application (NDA).
- 08 Apr 2026 Status changed from not yet recruiting to recruiting.
- 08 Apr 2026 According to a Vanda Pharmaceuticals media release, company announced the initiation of this trial.